March 28, 2017
1 min read
March 27, 2017
The high cost of innovator medicines often makes media headlines, but what about when it comes to generic drug pricing?
1 min read
March 27, 2017
Professor Steven Ley runs a research group at the Whiffen and Innovative Technology Centre in the Department of Chemistry, University of Cambridge, UK – and a significant focus of the group’s work right now is on flow chemistry and organic synthesis. We catch up with Daniel Fitzpatrick, a PhD student with the group, to find out how the group is working to synthesize a range of APIs on a single reactor platform that uses flow chemistry and a clever cloud-based system.
1 min read
March 27, 2017
Marathon sells Emflaza to PTC Therapeutics, but questions remain about FDA approval processes
1 min read
March 23, 2017
From bench chemist to a general manager, small molecule APIs have always been a strong focus for Bernhard Paul. Here, he describes his career transition, and offers his take on the latest API trends.
1 min read
March 23, 2017
Can high density cryopreservation allow biopharma manufacturers to buy back time? The answer is “yes” – and specialized media (both catalogue and customized) for perfusion processes are being designed for this purpose.Can high density cryopreservation allow biopharma manufacturers to buy back time? The answer is “yes” – and specialized media (both catalogue and customized) for perfusion processes are being designed for this purpose.
1 min read
March 23, 2017
President Trump’s verbal assault on the industry is a manifestation of long-standing underlying structural issues that have been poorly addressed over time. It’s time for a change of direction for the industry.
1 min read
March 23, 2017
Professor Lee Cronin, Regius Chair of Chemistry at Glasgow University, UK, has interests ranging from the origins of life to making drugs on Mars. Here, he shares his vision for the future of drug manufacturing.
1 min read
March 23, 2017
The manufacture of cell therapies, antibodies, or other biologic drugs is a complex and time-consuming process that many would feel does not lend itself to “on-demand” systems. But synthetic biology could help to re-write the rules of biopharma production.
1 min read
March 23, 2017
Three researchers at the Massachusetts Institute of Technology – chemical engineer Klavs Jensen, chemist Tim Jamison, and crystallization expert Allan Myerson – decided to collaborate and bid for a DARPA grant, resulting in a pharmacy on demand system based on continuous chemical flow processing.
1 min read
